Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, reported financial results for the quarter ended September 30, 2021, and provided a business update.
November 4, 2021
· 9 min read